Compare Cassava Sciences Inc (FLNA) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Mercadolibre Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Mercadolibre Inc trades at $1,856.78 (market cap $93.44B). The key difference: Mercadolibre Inc is far larger — about 1758.4× Cassava Sciences Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MELI | |
|---|---|---|
Market Cap | $53.14M | $93.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $2.51K |
52-Week Low | $1.09 | $1.55K |
Enterprise Value | -$33.43M | $100.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
MercadoLibre (MELI) trades at $1,873.88, showing modest daily gains of 0.35% amid a generally bullish technical outlook. The stock exhibits strong fundamental growth with 2025 revenue reaching $28.89B and net income of $2.00B, though recent quarterly EPS results have missed analyst expectations. The company is strategically investing heavily in logistics, fulfillment, and fintech expansion, which is pressuring near-term margins but positioning for long-term market dominance in Latin America.
The investment outlook balances robust top-line growth and a dominant competitive position against margin compression from strategic investments and recent earnings misses. Wall Street sentiment remains overwhelmingly positive with a $2,230 consensus price target, but investors face risks from execution on growth investments, competitive pressures, and ongoing legal investigations highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
